Article · Wikipedia archive · Last revised Aug 12, 2026

4-AcO-DPT

4-AcO-DPT, also known as 4-acetoxy-N,N-dipropyltryptamine or as depracetin, is a psychedelic drug of the tryptamine family related to 4-AcO-DMT. It has been sold as a designer drug. It is an ester of 4-HO-DPT, a psychedelic tryptamine that was first synthesized by Alexander Shulgin. Anecdotal reports indicate that 4-AcO-DPT exerts psychoactive effects in humans, however the pharmacology of 4-AcO-DPT has not been examined. It has been identified in illicit products in Japan.

Last revised
Aug 12, 2026
Read time
≈ 1 min
Length
248 w
Citations
3
Source
Wikipedia ↗
4-AcO-DPT
Clinical data
Other namesDepracetin
Routes of
administration		Oral
Drug classSerotonergic psychedelic; Hallucinogen
ATC code
  • None
Identifiers
  • 3-[2-(diethylamino)ethyl]-1H-indol-4-yl acetate
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC18H26N2O2
Molar mass302.418 g·mol−1
3D model (JSmol)
  • CCCN(CCC)CCC1=CNC2=C1C(=CC=C2)OC(=O)C
  • InChI=1S/C18H26N2O2/c1-4-10-20(11-5-2)12-9-15-13-19-16-7-6-8-17(18(15)16)22-14(3)21/h6-8,13,19H,4-5,9-12H2,1-3H3
  • Key:KRUGABVNKKKCJN-UHFFFAOYSA-N

4-AcO-DPT, also known as 4-acetoxy-N,N-dipropyltryptamine or as depracetin, is a psychedelic drug of the tryptamine family related to 4-AcO-DMT. It has been sold as a designer drug.1 It is an ester of 4-HO-DPT, a psychedelic tryptamine that was first synthesized by Alexander Shulgin. Anecdotal reports indicate that 4-AcO-DPT exerts psychoactive effects in humans, however the pharmacology of 4-AcO-DPT has not been examined. It has been identified in illicit products in Japan.2

Use and effects

Interactions

Chemistry

Analogues

Analogues of 4-AcO-DPT include dipropyltryptamine (DPT), 4-HO-DPT (deprocin), 4-AcO-DMT (psilacetin), 4-AcO-DET (ethacetin), 4-AcO-DiPT (ipracetin), 4-AcO-MET (metacetin), 4-AcO-MPT, and 4-AcO-MiPT (mipracetin), among others.

Society and culture

Canada

4-AcO-DPT is not a controlled substance in Canada as of 2025.3

See also

See also

References

References

  1. Schifano F, Orsolini L, Papanti D, Corkery J (2017). Neuropharmacology of new psychoactive substances (NPS) : the science behind the headlines. Current Topics in Behavioral Neurosciences. Vol. 32. Cham, Switzerland: Springer. pp. 351–380. doi:10.1007/978-3-319-52444-3. ISBN 978-3-319-52444-3. S2CID 23812562. Retrieved 14 January 2021.
  2. Tanaka R, Kawamura M, Hakamatsuka T, Kikura-Hanajiri R (January 2021). "Identification of six tryptamine derivatives as designer drugs in illegal products". Forensic Toxicology. 39 (1): 248–258. doi:10.1007/s11419-020-00556-5.
  3. "Controlled Drugs and Substances Act". Department of Justice Canada. Retrieved 19 January 2026.
External links